1355620-31-3

Basic information

• Product Name: 5-(5-{2H-[1,3]dioxolo[4,5-g]quinazolin-8-yloxy}pyridin-2-yl)-2-[(4-fluorophenyl)amino]-3-methyl-3-pyrimidin-4-one
• Synonyms: 5-(5-{2H-[1,3]dioxolo[4,5-g]quinazolin-8-yloxy}pyridin-2-yl)-2-[(4-fluorophenyl)amino]-3-methyl-3-pyrimidin-4-one
• CAS NO: 1355620-31-3
• Molecular Weight: 484.446
• Mol File: 1355620-31-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-(5-{2H-[1,3]dioxolo[4,5-g]quinazolin-8-yloxy}pyridin-2-yl)-2-[(4-fluorophenyl)amino]-3-methyl-3-pyrimidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(5-{2H-[1,3]dioxolo[4,5-g]quinazolin-8-yloxy}pyridin-2-yl)-2-[(4-fluorophenyl)amino]-3-methyl-3-pyrimidin-4-one(1355620-31-3)
• EPA Substance Registry System: 5-(5-{2H-[1,3]dioxolo[4,5-g]quinazolin-8-yloxy}pyridin-2-yl)-2-[(4-fluorophenyl)amino]-3-methyl-3-pyrimidin-4-one(1355620-31-3)

Safety Data

• Hazardous Substances Data: 1355620-31-3(Hazardous Substances Data)

Upstream product

• 1061611-02-6 2-(4-fluoro-phenylamino)-5-(5-hydroxy-pyridin-2-yl)-3-methyl-3H-pyrimidin-4-one 
• 72700-23-3 8-chloro-[1,3]dioxolo[4,5-g]quinazoline 

Relevant articles and documents

C-Met inhibitors as novel fused ring heterocyclic derivatives

This invention relates to a novel fused quinazoline derivative (represented by the formula I) useful as a c-Met inhibitor, its synthesis and application for treating c-Met mediated disorders. In particular, this invention relates to a fused heterocyclic derivative useful as a c-Met inhibitor, its synthesis and application for treating c-Met mediated disorders.

NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS

Certain novel fused quinazoline derivatives of formula (I) as c-Met inhibitors, their synthesis and their uses for treating a c-Met mediated disorder. Methods for treating a c-Met-mediated disorder are also disclosed in the invention.